Oncology Today—June 8, 2026

This week’s Oncology update highlights regulatory approvals, priority review activity, late-stage clinical progress, diagnostic expansion, and advancing precision oncology strategies

In Today’s Newsletter

Dive deeper

🫁 IBI363 long-term NSCLC follow-up [1] [China • 01 Jun 2026]

https://en.innoventbio.com/InvestorsAndMedia/PressReleaseDetail?key=600
Context: Innovent and Takeda reported Phase 1 PoC follow-up for IBI363 (TAK-928; PD-1/IL-2α-bias bispecific fusion protein) in advanced IO-resistant NSCLC.
Key point: IBI363 monotherapy showed long-term survival signals in squamous and EGFR wild-type adenoNSCLC cohorts, with global Phase 3 activity underway or planned.
Implication: May influence prescriber choice and payer reviews pending full data.

🧬 FoundationOne CDx approvals for TALZENNA plus XTANDI [2] [US • 01 Jun 2026]

https://www.foundationmedicine.com/press-release/fda-approval-tissue-blood-therapy-mcrpc
Context: Foundation Medicine received FDA approvals for tissue and blood CGP tests in HRR gene-mutated metastatic castration-resistant prostate cancer.
Key point: FoundationOne CDx and FoundationOne Liquid CDx can identify patients for Pfizer’s TALZENNA (talazoparib) plus XTANDI (enzalutamide).
Implication: May expand screening, initiation, and follow-up at scale.

🇪🇺 Zepzelca plus atezolizumab EC approval [3] [EU • 01 Jun 2026]

https://pharmamar.com/en/the-european-commission-approves-pharmamars-zepzelca-lurbinectedin-for-the-treatment-of-extensive-stage-small-cell-lung-cancer-in-combination-with-atezolizumab/
Context: PharmaMar announced EC approval of Zepzelca (lurbinectedin) plus atezolizumab as first-line maintenance therapy for adult ES-SCLC.
Key point: Approval was based on IMforte Phase 3 data showing reduced risk of progression or death and reduced risk of death versus atezolizumab alone.
Implication: May influence prescriber choice and payer reviews pending full rollout.

👁️ Darovasertib combination OptimUM-02 data [4] [US • 01 Jun 2026]

https://media.ideayabio.com/2026-06-01-IDEAYA-Biosciences-and-Servier-Provide-Complete-Data-from-Phase-2-3-Registrational-OptimUM-02-Trial-of-the-Darovasertib-Combination-in-First-Line-HLA-A2-01-Negative-Metastatic-Uveal-Melanoma-in-a-Late-Breaking-Oral-Presentation-at-ASCO
Context: IDEAYA and Servier presented complete Phase 2/3 OptimUM-02 data in first-line HLA-A*02:01-negative metastatic uveal melanoma.
Key point: Darovasertib plus crizotinib improved median PFS, ORR, and DCR versus investigator’s choice therapy; OS was immature.
Implication: May influence prescriber choice and payer reviews pending full data.

🧪 Imdylltra EC approval in ES-SCLC [5] [EU • 01 Jun 2026]

https://investors.amgen.com/news-releases/news-release-details/european-commission-approves-amgens-imdylltrar-treatment
Context: Amgen received EC marketing authorization for Imdylltra (tarlatamab) monotherapy in ES-SCLC after progression on or after platinum chemotherapy.
Key point: Approval was based on DeLLphi-304, where Imdylltra improved overall survival versus standard chemotherapy.
Implication: May influence prescriber choice and payer reviews pending full data.

💊 Giredestrant FDA priority review [6] [US • 02 Jun 2026]

https://www.roche.com/media/releases/med-cor-2026-06-02
Context: Roche said the FDA accepted giredestrant NDA under priority review for adjuvant ER-positive, HER2-negative stage I–III breast cancer.
Key point: Filing was based on lidERA Phase 3 results showing reduced risk of invasive disease recurrence or death versus standard endocrine therapy.
Implication: May influence prescriber choice and payer reviews pending full data.

🧬 Camizestrant SERENA-6 update [7] [02 Jun 2026]

https://www.astrazeneca.com/media-centre/press-releases/2026/camizestrant-combination-delayed-time-to-first-progression-in-patients-with-advanced-hr-positive-breast-cancer-with-an-ESR1-tumour-mutation.html
Context: AstraZeneca reported updated Phase 3 SERENA-6 data in HR-positive, HER2-negative advanced breast cancer with emergent ESR1 mutation.
Key point: Switching to camizestrant plus a CDK4/6 inhibitor delayed first and second progression versus continuing AI plus CDK4/6 inhibitor.
Implication: May influence prescriber choice and payer reviews pending full data.

🧫 Agilent PD-L1 IHC 22C3 Dako Omnis expansion [8] [US • 02 Jun 2026]

https://www.agilent.com/about/newsroom/presrel/2026/02jun-ca26023.html
Context: Agilent received FDA approval to expand PD-L1 IHC 22C3 pharmDx on Dako Omnis across ESCC, TNBC, cervical cancer, and gastric or GEJ adenocarcinoma.
Key point: The approval supports identification of patients who may be eligible for KEYTRUDA (pembrolizumab) in additional FDA-approved indications.
Implication: May expand screening, initiation, and follow-up at scale.

🧬 Candel aglatimagene Lancet Oncology publication [9] [US • 02 Jun 2026]

https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-announces-publication-lancet-oncology
Context: Candel published pivotal Phase 3 data for aglatimagene besadenovec (CAN-2409) plus valacyclovir with radiotherapy in localized prostate cancer.
Key point: The peer-reviewed data showed improved disease-free survival versus placebo plus valacyclovir, without increased clinically significant toxicity.
Implication: May influence prescriber choice and payer reviews pending full data.

🫁 MAIA THIO-104 enrollment update [10] [04 Jun 2026]

https://ir.maiabiotech.com/news-events/press-releases/detail/177/maia-biotechnology-reports-strong-enrollment-and-dosing
Context: MAIA reported enrollment and dosing progress in THIO-104, a pivotal Phase 3 trial of ateganosine in third-line advanced NSCLC.
Key point: The company said patients had been dosed across activated sites in multiple countries and targets further enrollment by year-end.
Implication: Signals pipeline investment and modality expansion.

Why it matters

• Lung cancer remained the densest theme, spanning ES-SCLC approvals, IO-resistant NSCLC development, and third-line NSCLC enrollment.
• Precision oncology infrastructure advanced through Foundation Medicine and Agilent diagnostic approvals.
• Oral SERDs continued moving across early and advanced ER-positive breast cancer, with Roche and AstraZeneca highlighting distinct settings.
• Regulatory momentum was strongest in the US and EU, with multiple approvals or accepted filings tied to biomarker-defined use.
• Several datasets were presented or updated around ASCO, reinforcing oncology’s mid-year catalyst window.

📚 View the full Oncology archive on our research hub page